Plain-English translation of NCT04996017 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a large study testing whether a medication called atezolizumab can help patients with pleural mesothelioma (cancer of the lung lining) after they've had surgery to remove the tumor. Half the patients will receive atezolizumab, and half will receive a placebo (a fake medication that looks identical). The study will track whether the medication helps keep the cancer from returning.
Mesothelioma is a serious cancer, and even after surgery removes the visible tumor, cancer sometimes comes back. Researchers believe this new immune-boosting treatment might help the body's own defenses prevent that recurrence.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the medication or a placebo, given as an infusion every 3 weeks for up to 12 months (or until the cancer returns or side effects become too severe). You'll have CT scans every 12 weeks for 2 years to check whether the cancer is coming back, along with regular blood tests and quality-of-life questionnaires. Your cancer tissue will also be studied to help researchers understand how the medication works.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Italy